TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05990790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
Study: NCT05461287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31904
Description: QLS31904 ONLY
Study: NCT05723757

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Draw a 8.5mL blood sample for detection of SNPs of genomic origin
Study: NCT06126458

Intervention type: OTHER
Intervention: shooting performance
Description: collecting total points after 72 target shootings done

Intervention type: OTHER
Intervention: shooting performance
Description: collecting total points after 72 target shootings done
Study: NCT04530383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: 500-1000 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: 500-1000 mg twice daily
Study: NCT04489290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D005 Vaginal Mousse
Description: D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05519566

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Retrograde Urethrogram
Description: Fluoroscopy Retrograde Urethrogram Vs the Traditional Retrograde Urethrogram

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Urethrogram
Description: Fluoroscopy Retrograde Urethrogram Vs the Traditional Retrograde Urethrogram
Study: NCT04806438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Patient will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice
Study: NCT05829798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNOLIS VA 80/160
Description: Single 4mL intra-articular injection of SYNOLIS VA 80/160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNOLIS VA 40/80
Description: Single 2mL intra-articular injection of SYNOLIS VA 40/80
Study: NCT06409234

Intervention type: OTHER
Intervention: Transthoracic Echocardiography Recieved
Description: Transthoracic Echocardiography Recieved
Study: NCT05852665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided resection
Description: Ultrasound-guided resection of buccal squamous cell carcinomas
Study: NCT05970705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: this anti-angiogenesis targeting drug is one of the standard third-line treatment options for patients with metastatic colorectal cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: this anti-angiogenesis targeting drug is one of the standard third-line treatment options for patients with metastatic colorectal cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: this chemotherapeutic drug is also one of the standard third-line treatment options for patients with metastatic colorectal cancer
Study: NCT05922982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine weaning protocol
Description: MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine weaning protocol and guided by the HPI
Description: MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI\<80) delivered by the Acumen IQ medical device.
Study: NCT06159179

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Medical thoracoscopy
Description: Medical thoracoscopy is a minimally invasive procedure to have access to pleura with combination of visual and medical instrument. The procedure is done with local and light anesthesia. Medical thoracoscopy plays role in basic diagnosis and therapeutic. A Flex-rigid thoracoscope will be inserted through the trocar cannula in the rigt or left mid axillary line of the hemithorax
Study: NCT05597813

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microneedling
Description: 15 patients will be subjected to microneedling alone. Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microneedling with topical timolol 0.5%
Description: 15 patients will be subjected to microneedling with topical timolol 0.5%.Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
Study: NCT06179121

Intervention type: OTHER
Intervention: DNA test for screening HLA-DQ2 and DQ8 from dried blood spots to early detect Celiac Disease
Description: Phase 1 and 2: After blood collection (in combination with regular care) and informed consent, a blood droplet obtained by an additional fingerprick (Phase 1 and just an extra droplet from an existing finger prick for Phase 2) will be deposited on filter paper S\&S 903™ (Schleicher and Schuell). DNA will be isolated using the QIAamp method designated for this purpose from dried blood spots (Qiagen). The results of the HLA-DQ2 and DQ8-typing using the dried blood spots will be compared with the results of the traditional HLA-typing. Factors that may influence the quality of the material will be taken into account in the validation process.

Intervention type: OTHER
Intervention: DNA test for screening HLA-DQ2 and DQ8 from dried blood spots to early detect Celiac Disease
Description: Phase 1 and 2: After blood collection (in combination with regular care) and informed consent, a blood droplet obtained by an additional fingerprick (Phase 1 and just an extra droplet from an existing finger prick for Phase 2) will be deposited on filter paper S\&S 903™ (Schleicher and Schuell). DNA will be isolated using the QIAamp method designated for this purpose from dried blood spots (Qiagen). The results of the HLA-DQ2 and DQ8-typing using the dried blood spots will be compared with the results of the traditional HLA-typing. Factors that may influence the quality of the material will be taken into account in the validation process.
Study: NCT05249608

Intervention type: DEVICE
Group type: OTHER
Intervention: A prospective, open-label, multicenter, single-arm clinical study to evaluate the safety and performance of the Gastric Bypass Stent System as a weight loss treatment for obesity
Description: This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 9 months.
Study: NCT04627922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers with current tobacco use disorder and cannabis use will be randomized to receive NAC 3600 mg per day over 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers and cannabis users with current tobacco use disorder will be randomized to receive placebo per day over 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants in both groups will receive 8 weekly cognitive behavioral therapy sessions for substance use disorder targeting both tobacco and cannabis use.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants in both groups will receive 8 weekly cognitive behavioral therapy sessions for substance use disorder targeting both tobacco and cannabis use.
Study: NCT05035147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin-bound paclitaxel
Description: Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle
Study: NCT06196775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104+AK112
Description: Cadonilimab (AK104): 10mg/kg or 15mg/kg Q6W iv D8 (dose choosing depends on the outcome of the dose climb stage) AK112: 20mg/kg Q3W iv D1 Eligible patients will receive AK104 plus AK112 until disease progression or withdrawn ICF or death, whichever comes first.
Study: NCT06331455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Two doses of durvalumab (1500 mg IV)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Non-ablative oligofractionated radiation (NORT)
Description: 12 Gy of Radiation in 3 fractions
Study: NCT06441253

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Deep Friction massage
Description: The calf muscles received a firm, deep-circulation massage with fingertip pressure

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: Four stretching exercises were performed for twenty minutes, five minutes for each technique, and eight to ten repetitions of each exercise (calf wall stretch, back knee straight, bilateral calf stretches, knees straight, ankle plantarflexion/dorsiflexion)
Study: NCT05908851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mL of 0.9% normal saline (57ml), 0.5% ropivacaine (40 ml), 10 mg morphine (10 mg/ml), 0.1 mg of epinephrine (0.1 mg/ml), and 30 mg of ketorolac (30 mg/ml)
Description: Ultrasound guided brachial plexus blockade
Study: NCT05695729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLYOMETRIC EXERCISE PROGRAM
Description: This group will perform following exercises in first four weeks. Reverse overhead throw Rotational wall throws Overhead medicine ball Chest passes Resistance tubing 90-90 external rotation~Frequency~* Rest between Exercises-: 60-120 Seconds~* Rest between Set of Exercise-: 45-60 Seconds after four weeks rest between exercise and rest between set of exercise will be reduced:~* Rest between Exercises-: 45-60 Seconds~* Rest between Set of Exercise-: 20-30 Seconds~Tools used:~Medicine Ball, Resistance band

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL EXERCISE PROGRAM
Description: This group will perform following exercise through out the session with different frequencies after 4 weeks Bench presses Triceps kickbacks bicep curls Overhead presses Push-ups~Frequency:~Rest between Exercises-: 60-120 Seconds Rest between Set of Exercise-: 45-60 Seconds~After 4 weeks the frequency will be:~Rest between Exercises-: 45-60 Seconds Rest between Set of Exercise-: 20-30 Seconds
Study: NCT06106880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wintergreen Throat Spray and Aspirin Tablet
Description: The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Throat Spray and Placebo Tablet
Description: The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wintergreen Throat Spray and Placebo Tablet
Description: The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Throat Spray and Placebo Tablet
Description: The placebo spray contained vehicle buffer, a sub-therapeutic dose of menthol, and a sweetener.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients.
Study: NCT06306170

Intervention type: RADIATION
Intervention: Image Guided Radiotherapy
Description: Patients treated with IGRT, IMRT, SBRT for Gynecological cancer will be evaluated
Study: NCT04915274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: uses of an application
Description: Patients will be advised that they can still use their QuestOnco handset if they are hospitalized only for a treatment-related toxicity.
Study: NCT04434326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14]CM082 suspension
Description: Before administration, the solid powder for administration was placed at room temperature. 40 ml drinking water was added into the drug container to prepare the suspension for the subjects to take. After that, 200 ml drinking water was used to repeatedly rinse the drug container for many times, and the subjects continued to take the lotion. Take care not to spill the liquid out of the bottle when shaking
Study: NCT04854759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride
Description: 100 mg, capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg, capsule
Study: NCT04927897

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: 3D endorectal ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Rectoscopy
Description: Rigid rectoscopy.

Intervention type: OTHER
Intervention: Scan, e.g. CT (resection specimen)
Description: For some patients, images of the resection specimen (note: NOT of the patients) during the pathological process will be acquired.
Study: NCT04850664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBOT + TAU
Description: The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time. It is paired with OFC-dependent cognitive tasks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham + TAU
Description: Sham CBOT device uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive tasks.
Study: NCT06169072

Intervention type: DRUG
Group type: OTHER
Intervention: Superparamagnetic Iron Oxide
Description: Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose

Intervention type: DEVICE
Group type: OTHER
Intervention: Technetium99
Description: Technetium99 +/- blue dye is injected per routine as a comparator and as back up.
Study: NCT05796362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oleogel (Oral and Rectal)
Description: Exploratory study of a novel oleogel dosage form of Azithromycin (Zithromax)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oleogel (Oral and Rectal)
Description: Exploratory study of a novel oleogel dosage form of Azithromycin (Zithromax)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Oleogel (Oral and Rectal)
Description: Exploratory study of a novel oleogel dosage form of Azithromycin (Zithromax)
Study: NCT04941053

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: seroprevalnce

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: seroprevalnce
Study: NCT05134987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0363-0845
Description: Participants will receive 0.5 nmol/kg NNC0363-0845 s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 3 nmol/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Description: Participants will receive 0.083 U/kg insulin detemir s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 0.5 U/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
Study: NCT06314100

Intervention type: DEVICE
Intervention: Tobacco heating systems
Description: The study aims to explore the effect of tobacco heating system consumption on microbiome of the supragingival dental biofilm and the risk of developing caries lesions

Intervention type: BEHAVIORAL
Intervention: cigarette smoking
Description: The study aims to explore the effect of cigarette smoking on microbiome of the supragingival dental biofilm and the risk of developing caries lesions

Intervention type: BEHAVIORAL
Intervention: non smoking
Description: The non smoking group of subjects serve as control for the other two groups
Study: NCT06117423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab-680LT
Description: First, adalimumab-680LT was administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure was performed to enable the visualisation and detection of fluorescence signals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab-680LT
Description: First, adalimumab-680LT was administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure was performed to enable the visualisation and detection of fluorescence signals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab-680LT
Description: First, adalimumab-680LT was administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure was performed to enable the visualisation and detection of fluorescence signals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab-680LT
Description: First, adalimumab-680LT was administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure was performed to enable the visualisation and detection of fluorescence signals.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Fluorescence Molecular Imaging was performed to enable the visualisation and detection of fluorescence signals.
Study: NCT04962997

Intervention type: OTHER
Intervention: Data collection
Description: Investigator will ensure the completion of a hetero-administered questionnaire which will be carried out in French, English, Portuguese or Spanish depending on the language spoken by the participant, including informations related to Demography and socio-economic conditions, Addictions, Work and studies, Housing, Health coverage, Gender and sexuality, Vulnerabilities and violence, Recourse to care, State of physical health, Mental Health, Prevention and Sexually Transmitted Infections (STIs), Checkup, Transition path and clinical complications and Dermatological problems.~Investigator will collect the data relating to the clinical examination, dermatological examination and the search for STIs (blood and / or urine) carried out in the routine care of the participant in a case report form (CRF).~The estimated duration of the interviews and the consultation is approximately 1 hour and 30 minutes per patient.
Study: NCT05446753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Animal-based meats
Description: Animal-based meats from beef, pork and chicken

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant-based meat alternatives
Description: Plant-based meat alternatives of beef, pork and chicken
Study: NCT06128096

Intervention type: DRUG
Intervention: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Description: Patients (180 diabetic patients with CAD that are using SGLT-2 inhibitors and 180 diabetic patients with CAD that are not using SGLT-2 inhibitors) who fulfil the inclusion and exclusion criteria will be recruited from the following sources:~UMMC Cardiology and Diabetes out-patient clinics UMMC Cardiology and Endocrinology in-patients (wards)~During the recruitment, patients will do baseline echocardiography in which includes epicardial adipose tissue and cardiac function. The same procedure will be repeated 6 months post intervention.
Study: NCT05775172

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: laparoscopic sleeve gastrectomy was done under general anesthesia by the same surgeon in the SBAHC. Routine preoperative, and postoperative care (including early post-operative dietary management) were done. Baseline assessment was taken within the last week before the surgery during the preoperative preparation and the final assessment was recorded 6 months after the surgery date.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Lifestyle intervention
Description: balanced 500 to 1000-calorie-deficit diet, personalized physical activity plan, and customized behavioral modification

Intervention type: OTHER
Intervention: Control
Description: No interventions were applied
Study: NCT05304234

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound or abbreviated MRI
Description: Abdominal ultrasound or abbreviated MRI

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound or abbreviated MRI
Description: Abdominal ultrasound or abbreviated MRI